Clinical Trials on Lymphoma, Follicular in United Kingdom

Total 5661 results

H. Lee Moffitt Cancer Center and Research Institute
BeiGene, Ltd.

Recruiting

Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas

Follicular Lymphoma | Marginal Zone Lymphoma | B-Cell Lymphoma

United States
Ronald Levy
Pfizer

Completed

A Phase 2 Intratumoral Injection PF-3512676 Plus Local Radiation in Low-Grade B-Cell Lymphomas

Lymphoma | Lymphoma, Non-Hodgkin | Lymphomas: Non-Hodgkin | Lymphomas: Non-Hodgkin Follicular / Indolent B-Cell

United States
Regeneron Pharmaceuticals

Recruiting

A Study to Learn How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Compared to Rituximab and Chemotherapy in Adult Participants With Previously Untreated Follicular Lymphoma (OLYMPIA-2)

Follicular Lymphoma (FL)

Spain, United States, Turkey, Thailand, Belgium, Poland, Chile, Italy
Genmab
AbbVie

Recruiting

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1)

Follicular Lymphoma (FL)

Austria, Greece, Israel, Korea, Republic of, Spain, Hungary, Sweden, Switzerland, France, Poland, Taiwan, Australia, Denmark, New Zealand, Turkey, Italy, Netherlands, Belgium, Canada, South Africa, Czechia, Brazil, Germany, Argentina, United... and more
University of Washington
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma

United States
Enterome

Recruiting

A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma (SIDNEY)

Follicular Lymphoma | Marginal Zone Lymphoma

United States, Italy, Spain
Ohio State University Comprehensive Cancer Center

Active, not recruiting

Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma and other conditions

United States
GlaxoSmithKline

Terminated

A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple Myeloma

Neoplasms | Cancer

United States, United Kingdom, France
Archigen Biotech Limited

Completed

A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients With Low Tumor Burden Follicular Lymphoma (RAMO-2)

Lymphoma, Follicular

United States, Korea, Republic of, Hungary, Spain, Turkey, Czechia, Italy, France, United Kingdom, Germany, South Africa, Australia, Chile, Mexico
MEI Pharma, Inc.

Terminated

Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL)

Marginal Zone Lymphoma | Non Hodgkin Lymphoma | Follicular Lymphoma (FL)

United States, Spain, Korea, Republic of, Belgium, Taiwan, Germany, France, Italy, Australia, Poland, New Zealand, United Kingdom, Austria, Switzerland
Millennium Pharmaceuticals, Inc.

Completed

Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma

Relapsed Follicular Lymphoma

United States, Puerto Rico
Hoffmann-La Roche

Completed

A Study of Obinutuzumab in Combination With Chemotherapy in Participants With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma (GAUDI)

Non-Hodgkin's Lymphoma

Spain, France, United Kingdom, Germany, Australia, Italy
Ascenta Therapeutics

Completed

Safety & Efficacy Study of AT-101 in Combination w/ Rituximab in Previously Untreated Grade I-II Follicular Non-Hodgkin's Lymphoma

Follicular Lymphoma

United States
Pharmacyclics LLC.

Completed

Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma

Follicular Lymphoma | B-cell Lymphoma | Non-Hodgkin's Lymphoma

United States
BeiGene

Active, not recruiting

A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma (ROSEWOOD)

Relapsed/Refractory Follicular Non-Hodgkin Lymphoma

Korea, Republic of, New Zealand, United States, China, Taiwan, Spain, Italy, Australia, Canada, United Kingdom, Belarus, Bulgaria, Czechia, France, Germany, Poland, Russian Federation
Seagen Inc.

Terminated

Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma

Lymphoma, Large B-Cell, Diffuse | Follicular Lymphoma, Grade 3b | Lymphoma, B-cell | Lymphoma, Follicular, Grade 3b

United States
University of Washington
Bayer

Terminated

Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma

Non-Hodgkin's Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Follicular Lymphoma | Grade 3b Follicular Lymphoma

United States
University of Washington
Bristol-Myers Squibb

Active, not recruiting

Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory Plasma Cell Myeloma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma and other conditions

United States
Roswell Park Cancer Institute

Not yet recruiting

Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies

Recurrent Mantle Cell Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic Leukemia | Refractory Mantle Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma | Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell... and other conditions

United States
Gilead Sciences

Completed

Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas (DELTA)

Follicular Lymphoma | Marginal Zone Lymphoma | Lymphoplasmacytic Lymphoma | Small Lymphocytic Lymphoma

United States, United Kingdom, Italy, Germany, Poland, France
University of California, Davis
Novartis

Completed

Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer

Multiple Myeloma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Adult Hodgkin Lymphoma | Refractory Chronic Lymphocytic Leukemia

United States
Stanford University
National Institutes of Health (NIH); Amgen

Completed

Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment

Lymphoma, Non-Hodgkin | Lymphomas: Non-Hodgkin | Lymphomas: Non-Hodgkin Peripheral T-Cell | Lymphomas: Non-Hodgkin Cutaneous Lymphoma | Lymphomas: Non-Hodgkin Diffuse Large B-Cell | Lymphomas: Non-Hodgkin Follicular / Indolent B-Cell | Lymphomas: Non-Hodgkin Mantle Cell | Lymphomas: Non-Hodgkin Marginal... and other conditions

United States
Marcela V. Maus, M.D.,Ph.D.

Recruiting

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Non-Hodgkin Lymphoma | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Non-hodgkin Lymphoma | High-grade B-cell Lymphoma | Grade 3b Follicular Lymphoma | Relapsed Non-Hodgkin Lymphoma

United States
Memorial Sloan Kettering Cancer Center
MethylGene Inc.

Terminated

Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

Lymphoma | Relapsed and Refractory | Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

United States
National Cancer Institute (NCI)

Completed

Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Splenic Marginal Zone Lymphoma | Anaplastic Large Cell Lymphoma | Recurrent Adult Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent... and other conditions

United States
Kami Maddocks, MD
Novartis

Completed

Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone... and other conditions

United States
Massachusetts General Hospital
GlaxoSmithKline; Dana-Farber Cancer Institute; Beth Israel Deaconess Medical...

Completed

Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma

Follicular Lymphoma | Marginal Zone Lymphoma | Small Lymphocytic Lymphoma

United States
GlaxoSmithKline

Withdrawn

A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen

Lymphoma, Follicular | Lymphoma, Non-Hodgkin | Lymphoma, Small Cleaved-Cell, Follicular | Lymphoma, Large-Cell, Follicular

United States
Allogene Therapeutics

Active, not recruiting

Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma (ALPHA)

Relapsed/Refractory Follicular Lymphoma | Relapsed/Refractory Large B Cell Lymphoma

United States
Memorial Sloan Kettering Cancer Center
Janssen Scientific Affairs, LLC; Novartis Pharmaceuticals

Completed

A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma

Lymphoma | Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma

United States
Zhejiang DTRM Biopharma

Recruiting

Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas

Follicular Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Chronic Lymphocytic Leukemia | Richter's Transformation | Relapsed Chronic Lymphocytic Leukemia

United States
Jonathan Friedberg
National Cancer Institute (NCI); National Institutes of Health (NIH)

Active, not recruiting

A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma (ILyAD)

Follicular Lymphoma | Marginal Zone Lymphoma | Small Lymphocytic Lymphoma | Mucosal-Associated Lymphoid Tissue Lymphoma

United States
National Cancer Institute (NCI)

Terminated

Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Bristol-Myers Squibb

Completed

Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140)

Lymphoma

Australia, Italy, United States, Spain, Canada, United Kingdom, Germany, Belgium, France, Singapore, Sweden, Norway
Kami Maddocks, MD
Pharmacyclics LLC.

Active, not recruiting

Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent... and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Splenic Marginal Zone Lymphoma | Waldenstrom Macroglobulinemia | Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Extranodal Marginal Zone Lymphoma of Mucosa-Associated... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma

Mantle Cell Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Indolent Adult Non-Hodgkin Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Recurrent Indolent Adult Non-Hodgkin Lymphoma

United States
Hoffmann-La Roche

Terminated

A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)

Lymphoma, Large B-Cell, Diffuse | Follicular Lymphoma

United States, Australia, Germany, Korea, Republic of, New Zealand
M.D. Anderson Cancer Center

Recruiting

ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma

Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Richter Syndrome | Refractory Mantle Cell Lymphoma | Refractory Aggressive B-Cell Non-Hodgkin Lymphoma | Refractory High Grade B-Cell Lymphoma | Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | Refractory... and other conditions

United States
M.D. Anderson Cancer Center
Genentech, Inc.; Biogen

Completed

Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma

Lymphoma

United States
SecuraBio

Withdrawn

Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO)

Lymphoma

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

DNA Analysis in Predicting Response to Antibody Therapy in Patients With Follicular Lymphoma Treated on Clinical Trials CALGB-50402 or CALGB-50701

Lymphoma

United States
M.D. Anderson Cancer Center
CureTech Ltd

Completed

Monoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular Lymphoma

Lymphoma

United States
ADC Therapeutics S.A.

Terminated

Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma | Mantle Cell Lymphoma

Spain, United States
CTI BioPharma

Terminated

Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's Lymphoma

Lymphoma, Follicular | Lymphoma, Mixed-Cell, Follicular | Lymphoma, Small Cleaved-Cell, Follicular | Lymphoma, Low-Grade

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma

Hematopoietic and Lymphoid Cell Neoplasm | Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma | Recurrent... and other conditions

United States
Gemin X

Completed

Safety and Efficacy of Single Agent Obatoclax Mesylate (GX15-070MS) Followed by a Combination With Rituximab for Previously-untreated Follicular Lymphoma (FL)

Lymphoma, Follicular

United States
Duke University
Millennium Pharmaceuticals, Inc.

Terminated

Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular Lymphoma

Lymphoma, Follicular

United States
Incyte Corporation

Active, not recruiting

A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. (InMIND)

Follicular Lymphoma | Marginal Zone Lymphoma

Finland, United States, Spain, Korea, Republic of, Canada, Israel, Turkey, United Kingdom, Netherlands, Greece, Italy, France, Taiwan, Germany, Belgium, Japan, Czechia, Switzerland, Ireland, Poland, Ukraine, Australia, Denmark, Hungary, Swede... and more
University of Kansas Medical Center

Completed

Evaluate Rituximab in Obtaining PCR (Polymerase Chain Reaction) Negative Leukapheresis Product in Patients With Relapsed Follicular Lymphoma

Non-Hodgkins Lymphoma

United States

Clinical Trials on Lymphoma, Follicular in United Kingdom

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Norway

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations